TRIM31抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human stomach cancer tissue, Primary antibody: P08708(TRIM31 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08708(TRIM31 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P08708(TRIM31 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The TRIM31 antibody is a research tool designed to detect and study the TRIpartite Motif-containing protein 31 (TRIM31), a member of the TRIM family involved in diverse cellular processes, including innate immunity, cancer progression, and antiviral responses. TRIM31 functions as an E3 ubiquitin ligase, mediating protein ubiquitination to regulate signaling pathways such as NF-κB and MAPK, which are critical in inflammation, apoptosis, and stress responses. It also interacts with mitochondrial proteins, influencing oxidative stress and metabolic homeostasis.

Antibodies targeting TRIM31 are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore its expression patterns, subcellular localization, and interactions. Studies highlight TRIM31’s dual roles: it acts as an oncogene in certain cancers (e.g., gastric, colorectal) by promoting proliferation and metastasis, while exhibiting tumor-suppressive effects in others. Additionally, TRIM31 modulates immune signaling by targeting viral RNA sensors (e.g., MDA5) or inflammasome components, impacting antiviral defenses and autoimmune disorders.

Validated TRIM31 antibodies are essential for understanding its context-dependent functions and therapeutic potential. Researchers rely on specificity-confirmed antibodies (monoclonal/polyclonal) to dissect TRIM31’s mechanisms in disease models, aiding drug discovery and biomarker development.